Citius Oncology Beats Q3 EPS Estimates with $0 Revenue

Citius Oncology reported a GAAP loss per share of ($0.08) for Q3 FY2025, beating analyst expectations by $0.07. No revenue was reported as LYMPHIR has not yet launched commercially. The company raised significant new capital but ended with just $112 in cash. The quarter highlighted progress toward launch readiness while raising concerns about near-term liquidity and ongoing losses.

Citius Oncology, Inc. (NASDAQ: CTOR) reported its fiscal third quarter 2025 results, highlighting progress towards the commercial launch of its lead product, LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma. The company reported a GAAP loss per share of ($0.08), beating analyst expectations by $0.07. No revenue was reported as LYMPHIR has not yet launched commercially.

The company raised significant new capital during the quarter, securing $12.5 million in financing through its parent company Citius Pharmaceuticals (NASDAQ: CTXR), with an additional $9 million raised by Citius Oncology itself in July 2025. Despite these capital raises, Citius Oncology ended the quarter with just $112 in cash, raising concerns about near-term liquidity.

The quarter saw a decrease in R&D expenses to $938,000 from $1.1 million year-over-year, reflecting the transition from development to commercialization. However, general and administrative (G&A) expenses increased to $1.9 million from $1.5 million, suggesting a scaling of administrative infrastructure ahead of commercial operations. The net loss widened to $5.4 million, or $0.08 per share, compared to $4.8 million, or $0.07 per share, in the prior year period, representing a 12.5% increase in net loss.

Citius Oncology is preparing for the U.S. launch of LYMPHIR™ in Q4 2025. The company has completed key pre-launch activities, including commercial-scale manufacturing, labeling, packaging, and distribution agreements. The successful transition from development to commercialization will be critical for Citius Oncology's financial trajectory, particularly as expenditures are likely to increase further with the upcoming product launch while revenue generation remains on the horizon.

References:

[1] https://www.stocktitan.net/news/CTOR/citius-oncology-inc-reports-fiscal-third-quarter-2025-financial-rxf5wze4dbs7.html

[2] https://www.stocktitan.net/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2025-tcm0q7vig80c.html

[3] https://www.nasdaq.com/press-release/citius-oncology-inc-reports-fiscal-third-quarter-2025-financial-results-and-provides